Peptide RX

back to claim graph

proof receipt / target

CXCR4-TMSB4-axis

CXCR4 / Thymosin-β4 axis (TB-500)

grade B status recovery receipt 5dfb807a5696 proof 33%

what this node claims

CXCR4-TMSB4-axis

CXCR4 / Thymosin-β4 axis (TB-500)

Open source surface

vertical proof spine

  1. 01 CXCR4-TMSB4-axis target / grade B / 70% 1 debt
  2. 02 Biased CXCR4 Partial Agonist for Progenitor Mobilization idea / grade C / 55%
  3. 03 Effect design run idea / grade C / 47% 1 debt
  4. 04 Effect design run idea / grade C / 47% 1 debt
  5. 05 CXCR4 WT fold / grade B / 66% 2 debt

evidence / risk instrument

42%
thin proof
structure evidence gates risk export lineage 42
visible debt pressure 40%
28%structuredebt
pLDDT pending
78%evidenceusable
grade B
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
33%lineagedebt
incomplete spine

proof completeness

33% missing alphafold_metric, candidate, finding, export
  1. 01 target
  2. 02 fold
  3. 03 alphafold metric
  4. 04 candidate
  5. 05 finding
  6. 06 export

Metrics and receipt inputs

binding partners
    context annotations
    0
    family
    GPCR_class_A
    functional sites
      gene symbol
      CXCR4
      go terms
        uniprot
        P61073

        AlphaFold metrics visual

        Confident backbone model

        82.3

        352 residues / min 31.7 / max 98.5 / source alphafold db

        PAE matrix for linked target
        Very high 57.4% 202 residues / >=90
        Confident 21.6% 76 residues / 70-89
        Low 8.2% 29 residues / 50-69
        Very low 12.8% 45 residues / <50

        usable fold context with explicit model-confidence limits

        Near-complete coverage / observed 352 of 352 residues.

        • residues 320-352 / mean 48.4
        • residues 1-26 / mean 39.48
        • residues 304-310 / mean 63.5
        • residues 29-34 / mean 63.78
        proof debt register

        Visible limits, not hidden cleanup.

        40%

        Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.

        medium missing functional-site annotations link target annotation, GO term, or binding-site context
        low computational-only status add independent evidence, challenge result, or witness review before strengthening
        medium no candidate yet leave visible until a stronger public receipt resolves it
        medium no candidate yet leave visible until a stronger public receipt resolves it
        medium no candidate yet leave visible until a stronger public receipt resolves it

        weakness and challenge edges

        What would stop this from becoming stronger.

        debt severity export claim strength next proof needed
        missing functional-site annotations medium visible weakens link target annotation, GO term, or binding-site context
        computational-only status low visible watch add independent evidence, challenge result, or witness review before strengthening
        no candidate yet medium visible weakens leave visible until a stronger public receipt resolves it
        no candidate yet medium visible weakens leave visible until a stronger public receipt resolves it
        no candidate yet medium visible weakens leave visible until a stronger public receipt resolves it

        what supports it

        idea names target idea:424da675-7641-45e6-91a0-ce7d20eacd6b -> target:529e55fe-c9ac-4db1-adcc-8cc266ab4833 targets / C / 0.44
        effect run matched target idea:effect-run:a3a674cc-7759-44f3-a24e-6da218931130 -> target:529e55fe-c9ac-4db1-adcc-8cc266ab4833 targets / C / 0.52
        effect run matched target idea:effect-run:bda9ca4e-79c2-4c9f-8670-b1418e4e3b9b -> target:529e55fe-c9ac-4db1-adcc-8cc266ab4833 targets / C / 0.52

        what it supports

        target has structure prediction target:529e55fe-c9ac-4db1-adcc-8cc266ab4833 -> fold:244554f9-4d1c-4942-abbc-a8c18e6783f1 folds_to / B / 0.823

        Research-use boundary

        This receipt describes public computational research state. It does not expose raw candidate sequences and does not make a clinical claim.